Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy

Affiliations

¹ Duke Cancer Institute, Durham, NC, USA; Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran.
² Duke Cancer Institute, Durham, NC, USA. Electronic address: thomas.polascik@dm.duke.edu.

Comment

Alireza Aminsharifi et al. Eur Urol. 2018 Aug.

. 2018 Aug;74(2):234-235.

doi: 10.1016/j.eururo.2018.01.022. Epub 2018 Feb 7.

¹ Duke Cancer Institute, Durham, NC, USA; Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran.
² Duke Cancer Institute, Durham, NC, USA. Electronic address: thomas.polascik@dm.duke.edu.

No abstract available

Comment on

Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.
De Bruycker A, Lambert B, Claeys T, Delrue L, Mbah C, De Meerleer G, Villeirs G, De Vos F, De Man K, Decaestecker K, Fonteyne V, Lumen N, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, Duthoy W, Ost P. De Bruycker A, et al. BJU Int. 2017 Dec;120(6):815-821. doi: 10.1111/bju.13938. Epub 2017 Jul 16. BJU Int. 2017. PMID: 28646594